In addition, targeting EZH2 has been found to promote antigen presentation in tumor cells and reverse resistance to anti-PD-1 therapy by reducing histone H3K27me3 modification on the β-2-microglobulin (B2M) promoter [193]. The gene discussed is PDCD1; the disease is neoplasm.